Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective StudyShigeo Shimose, Takuji Torimura, Hideki Iwamoto et al.|Cancers|2020Cited by 78
Effects of in‐hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver diseaseShunji Koya, Takuji Torimura, Takumi Kawaguchi et al.|Hepatology Research|2016Cited by 71
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse EventsHideki Iwamoto, Takuji Torimura, Hironori Koga et al.|Cancers|2020Cited by 68
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort studyMasahito Nakano, Masatoshi Tanaka, Ryoko Kuromatsu et al.|Cancer Medicine|2015Cited by 65
Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysisShigeo Shimose, Takuji Torimura, Takumi Kawaguchi et al.|Oncology Letters|2020Cited by 64